USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Emfit OY

USPTO PatentsView assignee record - 7 granted patents across 4 technology areas, recorded in grant years 2018–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61B (DIAGNOSIS; SURGERY; Identification).

RSS updates for this company

The verdict

According to USPTO PatentsView, Emfit ranks #35,175 of 49,997 tracked US assignees by granted-patent volume, with 7 patents across 4 technology areas.

#35,175
of 49,997 US assignees by volume
Top 35%
by Innovation Score (40.5/100)
10.4
avg claims per patent
+300%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R35175 · Foreign Corporation #35,175 · 7 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-PAR · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

  • GRANTS-MICRO 7 grants
  • MID-PACK #35,175/49,997
  • PHOTO-FINISH Eloxx Pharmaceuticals
  • CPC-NARROW A61B · 4 areas
  • INNOV-PAR 40.5/100
  • CLAIMS-PAR 10.4 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • VEL-SURGE +300% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Eloxx Pharmaceuticals Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Emfit’s 40.5 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Emfit

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Emfit's Innovation Score is 40.5/100 (top 35% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Emfit?

Each dot is one of Emfit’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Emfit’s own 10.4 claims/patent is at or below the 15.9 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Emfit vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 6.97.07.077.07.07.1 51015202530 Granted patents (volume) Avg claims / patent Eloxx Pharmaceuticals Ltd. - 7, 18Eloxx Pharmaceuti…Elyse Enterprises LLC - 7, 17.86Elyse EnterprisesEmbr Labs IP LLC - 7, 26.71Embr Labs IPEmefcy Ltd. - 7, 20EmefcyEmisense Technologies, LLC - 7, 14.71EmisenseEmmeci S.P.A. - 7, 14.71Emmeci S P AEmonster Inc - 7, 15.86EmonsterEMP IP Holding Company, LLC - 7, 14.71EMP IP HoldingEmfit OY - 7, 10.43Emfit OY
Emfit vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Emfit's grants concentrate

Emfit OY is a focused PatentsView assignee: 4 CPC subclasses with 57.1% of grants classified under A61B (DIAGNOSIS; SURGERY; Identification). Peak complete grant year is 2022 (2 grants) versus a trough of 1 in 2018. By volume, Emfit sits between Eloxx Pharmaceuticals Ltd. and EMP IP Holding Company, LLC.

Emfit's three-year grant acceleration

Emfit OY shows 3 grants in 2022–2024 against only 1 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Emfit's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Emfit holds 7 patents at rank #35,135, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Emfit

By rank, the assignees closest to #35,135 in granted patent volume.

Leaders in A61B (Diagnosis)

Other assignees with the most granted patents in Emfit's primary technology class.

Emfit's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

41 Top 35% higher than 65% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0.511.522.5 20182021202220242025 2
USPTO utility patent grants by year · 2018–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.

View data table
Emfit OY patent grants by year, 2015–2025
Year Patents Granted Share of Period
2018 1 14.3%
2021 1 14.3%
2022 2 28.6%
2024 1 14.3%
2025partial year 2 28.6%

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

What to do with this data

Emfit OY's patent record in context - here's where to go next.

  • Emfit OY's lead technology class is A61B (DIAGNOSIS; SURGERY; Identification), 57.1% of its portfolio - see every assignee active in that class. Explore A61B
  • Ranked #35,175 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Emfit OY against Eloxx Pharmaceuticals Ltd., an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 40.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.